Immunomic Therapeutics to present at BIO-Europe
The company’s CEO, William Hearl, also participated in the event’s Monday educational seminar titled “Land of the Rising Sun: Also the land of opportunity for new business development.”
The clinical biotechnology company uses its exclusively licensed LAMP technology from Johns Hopkins University to develop vaccines for a variety of ailments, including allergies. Based in Pennsylvania, Immunomic Therapeutics, has created the ARA-LAMP-Vax Peanut Allergy vaccine, Multi-Allergen vaccines, Mountain Cedar allergies vaccines, and Japanese Red Cedar vaccines.
"Presenting at these conferences presents Immunomic Therapeutics with a tremendous opportunity to convene with potential partners and investors, while explaining the incredible potential of our LAMP-vax platform," Hearl said. "We are particularly gratified to be part of the additional session outlining opportunities in Japan based on our recent licensing partnership with Astellas Pharma to develop our vaccine for Japanese Red Cedar allergy there."
Tuesday's session will begin at 4 p.m. Immunomic Therapeutics last presented at the 8th Annual European Life Sciences CEO conference in Zurich.